Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)

Diabetes Care

Volumn 27, Issue 7, 2004, Pages 1735-1740

  Pyörälä, Kalevi ^a   Ballantyne, Christie M ^b   Gumbiner, Barry ^c   Lee, Michael W ^c   Shah, Arvind ^c   Davies, Michael J ^c   Mitchel, Yale B ^c   Pedersen, Terje R ^d   Kjekshus, John ^e  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; STROKE; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CORONARY DISEASE; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METABOLIC SYNDROME X; MIDDLE AGED; PLACEBOS; SIMVASTATIN; TIME FACTORS;

EID: 3042755369     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.7.1735     Document Type: Article

References (22)

1. Reaven GM: Banting lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
2. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
3. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
5. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356-359, 2002
6. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, Morris R, Zavaroni I, van Dam R, Feskins E, Gabriel R, Diet M, Nilsson P, Hedblad B: Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 28: 364-376, 2002
7. The DECODE Study Group: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non-diabetic European men and women. Arch Intern Med. In press
8. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52:1210-1214, 2003
9. Ford ES, Giles WH: A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 26:575-581, 2003
10. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
11. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716, 2002
12. Hunt K, Resendez R, Williams S, Stern M: NCEP versus WHO metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study (SAHS) (Abstract). Diabetes 52 (Suppl. 1): A221, 2003
13. McNeill AM, Girman CJ, Rosamond W, Ballantyne CM: A new definition of the metabolic syndrome predicts incident coronary heart disease and ischemic stroke (Abstract). Circulation 106:II765, 2002
14. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, MacFarlane PW, Packard CJ, Cobbe SM, Shepherd J: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414-419, 2003
15. Girman CJ, Rhodes T, Mercuri M, Pyörälä K, Kjekshus J, Pedersen TR, Beere PA, Gotto AM Jr, Clearfield M, for the 4S Group and the AFCAPS/TexCAPS Research Group: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93: 136-141, 2004
16. The Scandinavian Simvastatin Survival Study Group: Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol 71:393-400, 1993
17. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
18. Kjekshus J, Pedersen TR: Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 76:64C-68C, 1995
19. Scandinavian Simvastatin Survival Study Group: Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 345: 1274-1275, 1995
20. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyöralä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ, for the Scandinavian Simvastatin Survival Study Group: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97:1453-1460, 1998
21. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K, for the Scandinavian Simvastatin Survival Study Group: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159:2661-2667, 1999
22. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J, for the Scandinavian Simvastatin Survival Study (4S) Group: Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104:3046-3051, 2001